Literature DB >> 35882670

Prognosis of metastatic bone cancer and myeloma patients and long-term risk of medication-related osteonecrosis of the jaw (MRONJ): some critical points.

Vittorio Fusco1, Maura Rossi2, Antonella Fasciolo3, Alessio Gambino4, Serena Palmeri5.   

Abstract

Entities:  

Year:  2022        PMID： 35882670     DOI： 10.1007/s00520-022-07214-z

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.359


× No keyword cloud information.
  6 in total

1.  Bone health in cancer: ESMO Clinical Practice Guidelines.

Authors:  R Coleman; P Hadji; J-J Body; D Santini; E Chow; E Terpos; S Oudard; Ø Bruland; P Flamen; A Kurth; C Van Poznak; M Aapro; K Jordan
Journal:  Ann Oncol       Date:  2020-08-12       Impact factor: 32.976

2.  Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update.

Authors:  Catherine Van Poznak; Mark R Somerfield; William E Barlow; J Sybil Biermann; Linda D Bosserman; Mark J Clemons; Sukhbinder K Dhesy-Thind; Melissa S Dillmon; Andrea Eisen; Elizabeth S Frank; Reshma Jagsi; Rachel Jimenez; Richard L Theriault; Theodore A Vandenberg; Gary C Yee; Beverly Moy
Journal:  J Clin Oncol       Date:  2017-10-16       Impact factor: 44.544

3.  Prognosis of metastatic bone cancer and myeloma patients and long-term risk of medication-related osteonecrosis of the jaw (MRONJ): some critical points.

Authors:  Vittorio Fusco; Maura Rossi; Antonella Fasciolo; Alessio Gambino; Serena Palmeri
Journal:  Support Care Cancer       Date:  2022-07-27       Impact factor: 3.359

4.  Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review.

Authors:  Terry L Ng; Megan M Tu; Mohammed F K Ibrahim; Bassam Basulaiman; Sharon F McGee; Amirrtha Srikanthan; Ricardo Fernandes; Lisa Vandermeer; Carol Stober; Marta Sienkiewicz; Ahwon Jeong; Deanna Saunders; Arif A Awan; Brian Hutton; Mark J Clemons
Journal:  Support Care Cancer       Date:  2020-06-13       Impact factor: 3.603

5.  Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors.

Authors:  T van Cann; T Loyson; A Verbiest; P M Clement; O Bechter; L Willems; I Spriet; R Coropciuc; C Politis; R O Vandeweyer; J Schoenaers; P R Debruyne; H Dumez; P Berteloot; P Neven; K Nackaerts; F J S H Woei-A-Jin; K Punie; H Wildiers; B Beuselinck
Journal:  Support Care Cancer       Date:  2017-09-30       Impact factor: 3.603

6.  Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases.

Authors:  B Beuselinck; P Wolter; A Karadimou; R Elaidi; H Dumez; A Rogiers; T Van Cann; L Willems; J-J Body; J Berkers; H Van Poppel; E Lerut; P Debruyne; R Paridaens; P Schöffski
Journal:  Br J Cancer       Date:  2012-11-06       Impact factor: 7.640
  6 in total
  1 in total

1.  Prognosis of metastatic bone cancer and myeloma patients and long-term risk of medication-related osteonecrosis of the jaw (MRONJ): some critical points.

Authors:  Vittorio Fusco; Maura Rossi; Antonella Fasciolo; Alessio Gambino; Serena Palmeri
Journal:  Support Care Cancer       Date:  2022-07-27       Impact factor: 3.359
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.